Slide 1: Glaukos: We'll Go First
GLAUKOS WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases.
Slide 2: Fiscal year 2024 net revenues up 22%
For fiscal year 2024, net revenues were approximately $383 million, up 22% compared to net revenues of approximately $315 million in 2023.
Slide 3: Annual Reported Net Sales
Annual Reported Net Sales (in millions) $400 $383 $315 $294 $283 237 $250 $ $225 $200 $181 $159 $150 $114 $100 $72 so 46 [ . i 2014 «#2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 t _ 10-Yr CAGR: 24%
Slide 4: U.S. Glaucoma
U.S. Glaucoma Our fourth quarter U.S. Glaucoma net revenues were approximately $56.3 million, representing year-over-year growth of 45% versus 4Q 2023 driven by growing contributions from iDose® TR . For fiscal year 2024, U.S. Glaucoma net revenues were approximately $199.6 million, represen
Slide 5: Dry Eye, Glaucoma, Presbyopia, Keratoconus
Dry Eye Glaucoma Presbyopia Ocular Hypertension and Open-Angle Glaucoma ———— Keratoconus
Slide 6: Product Patient Status
PRODUCT PATIENT STATUS Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) Glaucoma (failed on prior therapy) FDA Cleared (2022) cine a apa) tive PMA Study Advanced-Refractory Glaucoma OUS Approved / US IDE Open Ocular Hypertension - Glaucoma FDA Approved (2023) Ocular Hypertensi
Slide 7:
Slide 8: Our mission is to disrupt conventional treatment paradigms
Our mission is to disrupt conventional treatment paradigms to advance the existing standard of care and enrich the lives and treatment alternatives for patients worldwide suffering from sight-threatening chronic eye diseases. We believe our platforms and product candidates have the a
Slide 9: Program, Patient, Intended Clinical Benefit, 2025 Milestone Target
PROGRAM PATIENT INTENDED CLINICAL BENEFIT 2025 MILESTONE TARGET GLAUCOMA Mild-to-Moderate Glaucoma MIGS therapy Advance enrollment in PMA pivotal trial iStent infinite Advanced-Refractory Glaucoma PRESERFLO MicroShunt Piva fairest ‘Ab-externo device for late-stage glaucoma Commence US IDE trial Sust
Slide 10: Our platforms embody ambitious, big ideas
Our platforms embody ambitious, big ideas aimed at addressing large and chronically underserved eye diseases, including for glaucoma, corneal disorders, and retinal diseases. Over the years the number of disclosed pipeline programs associated with these platforms has expanded significantly to 14 e
Slide 11: iLution Transdermal Pharmaceuticals
iLution Transdermal Pharmaceuticals Our iLution transdermal pharmaceutical platform, which consists of patented cream-based drug formulations, are designed to be applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of e
Slide 12: Product Patient Status
PRODUCT PATIENT STATUS ti SLK-301) Dry Eye Phase 2 iLuti pia (GLK-302) Presbyopia Phase 2 iL 3 ‘Ocular Hypertension - Glaucoma Phase 2 pharitis Demodex Blepharitis Pre-Clinical
Slide 13: